IDO and TDO Inhibitors - Novel Immune Response Checkpoint Modulators; Competitor Analysis Report

The Competitive Intelligence report about IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators provides a competitor analysis as of March 2015 in the development pipeline of novel inhibitors of indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3- dioxygenase (TDO) for treatment of cancer as monotherapy and in combination with other immune checkpoint inhibitors. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report provides a compilation of active small molecule projects in research and development as specific IDO or TDO inhibitors as well as dual IDO & TDO inhibitors for treatment of cancer.

Competitor projects are listed in a tabular format providing information on:

• Drug Codes
• Target / Mechanism of Action
• Class of Compound
• Company
• Product Category
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 18 pages “Competitor Analysis: IDO & TDO Inhibitors - Novel Immune Response Checkpoint Modulators” report covers the Specific Indoleamine 2,3-Dioxygenase (IDO) Inhibitors, Specific Tryptophan 2,3- Dioxygenase (TDO) Inhibitors, Dual IDO & TDO Inhibitors, Corporate IDO & TDO Inhibitor R&D Pipelines.

For further information on this report, please visit- http://mrr.cm/4Gr

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology